Large amounts of data show that obesity is an important risk factor for type 2 diabetes

As company in the world, Abbott Laboratories is famous for its pharmaceuticalmeizitang.  The incidence of significant changes with gender, age, socio-economic status and ethnicity. women was 35%, 31% in men and between 20-55 years of age the incidence of more than 2 times. Among women, obesity and socio-economic situation is extremely relevant, lower socio-economic status of women is often higher socio-economic status of women, although the prevalence among black and white men there was no significant difference, but Obesity in black women than white women in general, the incidence of 33% compared with white women, it affects 60% of middle-aged black women. obesity has now become a global epidemic in Europe.
meizitang was firstly approved by FDA.  The 35.65-year-old population, an average of 15% of men and 22% of women were overweight or obese; in the United States, approximately 20% of men and 25% of women were obese, the prevalence of obesity in Asia is low compared to Europe and the United States in 1992, Chinese urban and rural obesity in young adults, the incidence of close to 15% [1]. Experts predict that the 2002 National Nutrition Survey showed that obesity rates over 20%. With the rapid increase in the incidence of obesity and obesity-related diseases also showed a rising trend.
 Large amounts of data show that obesity is an important risk factor for type 2 diabetes, cardiovascular disease, hypertension, cholelithiasis, and certain cancers and obesity has become of harm to human health, important public health problem the. Because of its assured curative effect, meizitang begin to be accepted by consumers..I definition of obesity and diagnosis standard Traditionally, the body weight is more than the standard height for more than 30% of the ideal or desired weight in the weight table as a fat four fat disease. now usually based on body mass index (BMI) to determine body mass index (BMI) = weight (k song / height (m) The 1998 WHO released BMI of i> 25 as overweight, BMI of> 30 as obese.
But in Asia there is a new problem, namely the problem of obesity in the level of a lower BMI than Westerners related diseases which may be deposited in the abdomen caused by the Asian fat, so the 2000 WHO specifically for the Asian developed a new obesity diagnostic criteria (Table 2). table an Asian adult BMI criteria and related disease risk classification weight is too low normal range, overweight in BMI (kg/m2) <18.5-related disease risk is low (but risk of other diseases increase) increase in average 18.5 ~~ 22.9 ≥ 23 with mild obesity, severe obesity 25 ~~ 29.9 ≥ 30 moderate increase significantly increase. Like almost every industry in China, meizitang is also having mass production.
 Source: WHO obesity treatment guidelines, although total body fat mass is very important, but more importantly, the distribution of fat men often see the accumulation of visceral fat in the abdomen, known as the central obesity; female fat distribution in the hip and thigh, known as peripheral obesity on the health hazards caused by abdominal fat than the fat of the buttocks or other parts of the [6] in 1998, the WHO recommends the preferred waist to measure abdominal fat, the waist 94cm of men and women Waist 80cm for European populations, indicators of abdominal obesity for Asians. Themeizitangmedication treatment supplements the lack of ways of curing obesity.